India grapples with ‘superbug’ surge: new data show one in six bacterial infections now treatment-resistant

1. The alarming headline: one in six infections resistant

In October 2025, WHO released its comprehensive “Global Antibiotic Resistance Surveillance Report 2025”, based on data from more than 23 million laboratory-confirmed infections collected across 104 countries during 2023. The headline figure: ~17 % of bacterial infections worldwide are now resistant to at least one key antibiotic in the pathogen–drug pair monitored by the Global AMR and Use Surveillance System (GLASS). That is, roughly one in every six cases of common infections—bloodstream, urinary tract, gastrointestinal, gonorrhoea—are no longer reliably treatable using standard antibiotics.

The report underlines that resistance is not evenly distributed. In regions such as South-East Asia and the Eastern Mediterranean, one in *three* infections were resistant. In Europe the rate was one in ten; in the Western Pacific roughly one in eleven.

The pace of increase is steep: for 40 % of monitored pathogen-drug combinations, resistance grew annually over the five years from 2018 to 2023 by 5-15%. The implication is clear: modern medicine’s main tools—common antibiotics—are losing effectiveness faster than new replacements are arriving.

2. Why India is especially at risk

India is one of the countries that contributes disproportionately to the global AMR burden. A recent Indian Express piece notes that among bloodstream, urinary tract, and gastrointestinal infections, India accounted for 41 % of bloodstream-infection articles in the WHO GLASS data set. Another study by Nature revealed that in 2019 only 7.8 % of patients with drug-resistant Gram-negative infections in India received appropriate therapy—a stark indicator of access and capacity gaps.

Experts highlight several Indian-specific drivers: high infectious-disease burden, widespread over-the-counter (OTC) antibiotic sales, incomplete dosage courses, weak antibiotic stewardship in smaller hospitals, large informal sector, and intensive livestock and agricultural antibiotic use (though less well documented).

India’s own surveillance data show worrying trends. The National Centre for Disease Control’s (NCDC) annual report for 2024 indicates rising carbapenem resistance in major pathogens—E. coli, Klebsiella, Pseudomonas and Acinetobacter species. For example, carbapenem-resistant E. coli isolates rose from ~27 % in 2022 to ~35 % in 2024; Klebsiella spp jumped from ~59% to ~70% in the same period. These numbers reflect tertiary hospitals; community data remain thin.

3. What the creeping reality means for patients and health systems

When antibiotics fail, even common infections become high-stakes. Urinary tract infections, pneumonia, septicemia—once treatable—are increasingly requiring last-resort drugs (colistin, newer β-lactam combinations), high-cost treatment, longer hospital stays and higher mortality. India’s high incidence of Gram-negative sepsis magnifies the risk.

Consider the regional hospital scenario: a patient with sepsis due to carbapenem-resistant Klebsiella may require prolonged ICU stay, expensive medications, and still face high mortality. For low-income families, the catastrophic cost of these failures can be ruinous, pushing households into poverty. From a systemic view, tertiary-care budgets, insurance covers and state-emergency finances are all under strain.

Globally, WHO estimates that drug-resistant infections contributed to 4.7 million deaths in 2021, including 1.14 million directly caused by resistant bacteria. The figure for India may be proportionally higher because of population, disease burden and health-system constraints.

4. The misuse backdrop: antibiotics everywhere, oversight nowhere

The Tamil-Nadu analogue of ‘free antibiotic’ culture persists: in pharmacies across India, antibiotics are often sold without prescription; patients self-medicate for viral illnesses, take incomplete courses, share medicines, persist on first-line meds when they fail. These practices drive selection of resistance.

In hospital settings too, antimicrobial stewardship programmes are patchy. Smaller institutions rarely track resistance trends; diagnostics are limited; empirical broad-spectrum use is common. A 2025 viewpoint in the *Journal of Global Health* warned that India’s antibiotic introduction policy lacks strategic regulation—new antimicrobials may be deployed without adequate stewardship frameworks, risking rapid resistance to them too.

5. One-Health realities: environment, animals, food chain

Resistance doesn’t sit in hospitals alone. The One-Health paradigm emphasises that antimicrobial use in animals, aquaculture, agriculture and spill-over into the environment matters. India’s documentation on animal and environmental AMR remains thin, but studies show high antibiotic residues in pharmaceutical-effluent zones, and high carriage of resistant bacteria in community settings. The NAMS task-force flagged neonatal deaths linked to resistant bacteria and called for integrated human-animal-environment surveillance.

6. Policy and regulatory cracks

India introduced Schedule H1 in 2014 (restricting OTC antibiotic sales) and launched the National Action Plan on AMR (NAP‐AMR) for 2017-21, but implementation has been weak. Monitoring of compliance, lab accreditation, and stewardship programmes remain sub-optimal. Journal literature argues that even new antibiotics entering India may lack controlled access, which risks resistance developing faster.

The new WHO surveillance data adds urgency: global resistance is building—and India must hurry. The report calls for countries to strengthen surveillance, stewardship, infection-prevention and control, antibiotics access-while‐conserving, and One-Health strategies.

7. Response glimpses: states & hospitals stepping up

Some Indian states are now moving: in September 2025, the state of Punjab launched a dedicated action plan under the One-Health framework—the Punjab State Action Plan for Containment of Antimicrobial Resistance (PUNJAB-SAPCAR). It becomes the seventh state to do so, signalling growing traction.

Hospitals too are upgrading: large tertiary institutions in Mumbai and Delhi report the growth of antimicrobial-stewardship (AMS) teams, daily resistance rounds, and data dashboards for prescribing practices. But the scale remains small relative to need.

8. What immediate measures India must adopt

The action checklist is clear—and urgent:

• Nation-wide surveillance expansion: Link all medical colleges, district hospitals and private labs into the AMR network; data must be publicly transparent.
• Regulate antibiotic dispensing: Enforce Schedule H1 strictly; digital prescription capture; penalties for OTC sale without prescription.
• Stewardship in every hospital: Mandatory AMS teams in all tertiary centres; diagnostics-led prescribing; automatic stop/trigger codes.
• One-Health mandates: Integrate veterinary, agriculture, environment agencies; monitor antibiotic use and residues in livestock and effluents.
• Public awareness campaigns: Massive national communication push on “finish the course”, “no antibiotics for viruses”, and safe use of antibiotics.
• Incentivise new drug development: Fast-track approvals for novel antibiotics, but tie use to stewardship systems so they don’t become ‘old drugs’ quickly.

9. The strategic importance for India’s health agenda

India’s progress in infectious-disease control—TB, HIV, malaria, childhood immunisation—has been recognised globally. But AMR threatens to roll back these wins. As India positions itself for higher-value healthcare exports, medical tourism, and expanded public-health insurance, failure to check AMR becomes a commercial and reputational risk.

Investors in pharma, diagnostics and health-IT must view AMR as not just a public-health issue but a business risk. Over-the-counter antibiotic misuse erodes market trust; diagnostics-led care becomes more essential; hospital-acquired infection control becomes a credential for insurance. For India to be the “pharmacy of the world” plus “healthcare destination of the world”, it must manage this Achilles heel.

10. Looking ahead: what 2030 could look like</ >

If progress stalls, projections suggest AMR may contribute to hundreds of thousands of deaths annually in India and billions of dollars of incremental cost by 2030 (HealthData estimate). On the other hand, if reforms scale, India could become a case study in middle-income country AMR containment—leveraging large domestic market, growing diagnostics industry and global export ambition.

Bottom line

The confrontation with antibiotic resistance is no longer a future threat—it’s already happening. For India, the stakes are high: public health, economic growth and global credibility. The new WHO data are a wake-up call. The question is: will India move from warnings to real enforcement, or will this be another epidemiological failure disguised as delay?